Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same

• US 6,534,676 B2
• Filed: 01/31/2001
• Issued: 03/18/2003
• Est. Priority Date: 01/31/2001
• Status: Expired due to Fees

• Current Assignee: Southern Arizona Veterans Affairs Health Care System, Arizona Board of Regents (University of Arizona)
• Original Assignee: Southern Arizona Veterans Affairs Health Care System, Arizona Board of Regents (University of Arizona)
• Inventors: Goldman, Steven, Pennock, Gregory D., Bahl, Joseph J., Morkin, Eugene
• Primary Examiner(s): Killos, Paul J.
• Application Number:
  US09/774,994
• Publication Number:
  US 20020151594A1
• Time in Patent Office: 776 Days
• Field of Search: 562/405, 514/557, 514/568
• US Class Current: 562/405
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 9/4866 Organic macromolecular compounds
• CPC Class Codes: A61K 9/7023 Transdermal patches and similar drug-containing composite devices, e.g. cataplasms galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

Applicants'"'"' invention includes a method to treat a patient having congestive heartfailure by administering a therapeutically effective amount of 3,5-diidothyropropionic acid. Applicants'"'"' invention further includes a method to lower cholesterol blood levels of a patient by administering a therapeutically effective amount of 3,5-diidothyropropionic acid. Applicants'"'"' invention further includes a synthetic method to prepare 3,5-diidothyropropionic acid.

Claims

1. A method for treatment of a human patient with congestive heart failure, comprising administering to the human patient a therapeutically effective amount of 3,5-diiodothyropropionic acid.

2. The method of claim 1, wherein 3,5-diiodothyropropionic acid is administered as a formulation selected from the group consisting of a liquid preparation, solid preparation, capsule preparation, and an implant preparation.

3. The method of claim 2, wherein said formulation further comprises a pharmaceutically acceptable carrier.

4. The method of claim 3, wherein said formulation further comprises at least one of a stabilizer, excipient, solubilizer, antioxidant, pain-alleviating agent, and an isotonic agent.

5. The method of claim 1, wherein said 3,5-diiodothyropropionic acid is administered by patenteral injection.

6. The method of claim 1, wherein said 3,5-diiodothyropropionic acid is administered by patenteral intravenous injection.

7. The method of claim 1, wherein said 3,5-diiodothyropropionic acid is administered orally.

8. The method of claim 1, wherein said 3,5-diiodothyropropionic acid is administered directly into the pulmonary system of the patient.

9. The method of claim 1, wherein said 3,5-diiodothyropropionic acid is administered transdermally.

10. The method of claim 1, wherein said 3,5-diiodothyropropionic acid is administered by implantation.

11. A method to lower cholesterol blood levels of a patient, comprising administering to the patient a therapeutically effective amount of 3,5-diiodothyropropionic acid.

12. The method of claim 11, wherein 3,5-diiodothyropropionic acid is administered as a formulation selected from the group consisting of a liquid preparation, solid preparation, capsule preparation, and an implant preparation.

13. The method of claim 12, wherein said formulation further comprises a pharmaceutically acceptable carrier.

14. The method of claim 13, wherein said formulation further comprises at least one of a stabilizer, excipient, solubilizer, antioxidant, pain-alleviating agent, and an isotonic agent.

15. The method of claim 11, wherein said 3,5-diiodothyropropionic acid is administered by patenteral injection.

16. The method of claim 11, wherein said 3,5-diiodothyropropionic acid is administered by patenteral intravenous injection.

17. The method of claim 11, wherein said 3,5-diiodothyropropionic acid is administered orally.

18. The method of claim 11, wherein said 3,5-diiodothyropropionic acid is administered directly into the pulmonary system of the patient.

19. The method of claim 11, wherein said 3,5-diiodothyropropionic acid is administered transdermally.

20. The method of claim 11, wherein said 3,5-diiodothyropropionic acid is administered by implantation.